Natera Inc. (NASDAQ: NTRA) will provide its Signatera circulating tumor DNA (ctDNA) testing platform to Angiex Inc. as part of a Phase I clinical trial evaluating AGX101, an investigational antibody-drug conjugate targeting TM4SF1-expressing tumor cells.
The study, registered under clinical trial identifier NCT06440005, will enroll patients with unresectable, locally advanced, or metastatic solid tumors. Angiex, a privately held biotechnology company based in Cambridge, Massachusetts, will use Signatera's longitudinal ctDNA measurements to monitor treatment response alongside standard radiologic assessments.
Paul Jaminet, co-founder and CEO of Angiex, said the collaboration aims to determine whether ctDNA tracking can complement imaging data, particularly in cases where metabolic or structural changes on scans may not clearly indicate viable tumor tissue. Eric Matthews, Natera's general manager of biopharma, noted that Signatera provides "additional depth into early biologic response assessment that can meaningfully advance our understanding of this novel drug class."
Natera operates CLIA-certified laboratories in Austin, Texas, and San Carlos, California. The company's Signatera test is designed to deliver personalized ctDNA profiling for cancer monitoring applications.
